Systemic therapy of hepatocellular carcinoma: Current status and future perspectives

Table 1 Efficacy results of molecular agents for advanced hepatocellular carcinoma

Molecular agent	Study phase	Results	Ref.
Sorafenib	III (Sharp) vs placebo	Median OS: 10.7 mo vs 7.9 mo	[31]
	III (Asian) vs placebo	Median OS: 6.5 mo vs 4.2 mo
			[32]
	II	Median OS: 13.7 mo vs 6.5 mo
	(sorafenib + doxorubicin vs doxorubicin)		[33]
Bevacizumab	II	Median OS: 12.4 mo	[43]
	II	Median OS: 9.6 mo	[45]
	(Beva + gemox)	Median OS: 15.0 mo	[48]
	II
	(Beva + erlotinib)
Sunitinib	II	Median OS: 9,8 mo	[49]
	II	Median OS: 8.0 mo	[50]
	III	Median OS: 7.9 mo 10.2 mo	[51]
	(Sunitinib vs sorafenib)
Brivanib	II	Median OS: 9.7 mo	[52]
	III
	BRISK-PS (Briv vs placebo)	Median OS: 9.4 mo vs 8.3 mo	[53]
	III
	BRISK-FL(Briv vs sorafenib)	Median OS: 9.5 mo vs 9.9 mo	[54]
ABT 869 (Inifanib)	II	Median OS: 9.7 mo	[55]
Pazopanib	I	Median TTP 4.5 mo	[56]
AZA2171 (Cediranib)	II	Median OS: 5.8 mo	[57]
Vatalanib (PTK787/ZK 222584)	I-II	Median OS: 7.3 mo	[58]
Tivantinib (ARQ 187)	II	Median OS 7.2 mo vs 3.8 wk	[59]
	(Tivant vs placebo)	(c-met High)
Ramucirumab	II	PFS 4.3 mo	[60]
Everolimus	I-II	PFS 3.8 mo	[75]
Erlotinib	II	Median OS: 13 mo	[67]
Gefitinib	II	Median OS: 6.5 mo	[69]
Lapatinib	II	Median OS: 6.2 mo	[70]
Cetuximab	II	Median OS: 9.6 mo	[71]

OS: Overall survival; TTp: Time to progression; PFS: Progression-free survival.